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Gender differences in lifetime psychiatric and substance use disorders 
among people who use substances in Barcelona, Spain 
 
Abstract 
Purpose 
To examine gender differences in lifetime substance use and non-substance 
use (non-SUD) psychiatric disorders among illicit drug users and determine 
factors associated with non-SUD psychiatric disorders independently for males 
and for females.   
Design  
Secondary analysis of five cross-sectional studies conducted in Barcelona, 
Spain during 2000-2006. Lifetime DSM-IV substance use and non-SUD 
psychiatric diagnoses were assessed using the Spanish Psychiatric Research 
Interview for Substance and Mental Disorders among 629 people who use 
substances (68% male) recruited from treatment (n=304) and out of treatment 
(n=325) settings. Odds ratios (OR) and 95% confidence intervals (CI) were 
calculated using binary logistic regression. 
Findings 
The prevalence of any lifetime psychiatric (non-SUD) disorder was 41.8%, with 
major depression (17%) and antisocial personality disorder (17%) being the 
most prevalent disorders. After adjusting for age and study, the odds of having 
any lifetime non-SUD (OR 2.10; 95%CI 1.48, 2.96); any mood disorder (OR 
2.13; 95%CI 1.46, 3.11); any anxiety disorder (OR 1.86; 95%CI 1.19; 2.92); any 
eating disorder (OR 3.09; 95%CI 1.47, 6.47); or borderline personality disorder 
(OR 2.30; 95%CI 1.36, 3.84) were greater for females than males.  Females 
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were less likely than males to meet criteria for antisocial personality disorder 
(OR 0.59; 95%CI 0.36, 0.96) and attention deficit disorder (OR 0.37; 95%CI 
0.17, 0.78).  
Research limitations/implications  
Psychiatric disorders are common among people who use substances, with 
gender differences reported for specific disorders.  Gender-sensitive integrated 
treatment approaches are required to prevent and to address comorbidity 
psychiatric disorders among this population. 
Originality/value 
This secondary analysis of five cross-sectional studies included a large sample 
size allowing sufficient power to examine differences between men and women. 
An additional strength of the methodology is the use of the gold standard 
PRISM which was used to assess disorders. 
 
Key words 
psychiatric disorders; substance use disorders; illicit drug users; Psychiatric 
Research Interview for Substance and Mental Disorders (PRISM); gender 
differences; secondary analysis. 
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Introduction  
The incidence of comorbid psychiatric disorders is higher among people who 
use substances than among people who do not (Flynn and Brown, 2008). The 
prevalence of comorbid substance use and psychiatric disorders ranges from 
15-100% depending on the population studied, the timeframe considered and 
the assessments used (Flynn and Brown, 2008; Torrens et al., 2015; Kingston 
et al., 2016). Among people who use substances from clinical and non-clinical 
populations, the most common mental health comorbid disorders are mood, 
anxiety, and personality disorders (Hasin et al., 2004; Torrens et al., 2015; 
Torrens et al., 2011; Kingston et al., 2016).  
Gender differences have been reported in the prevalence of co-occurring 
psychiatric disorders among people who use substances. Generally, women 
report higher prevalence than men of the following disorders: depression, 
anxiety, (including post-traumatic stress and panic disorders), eating disorders 
and borderline personality disorder, and men are more likely to report higher 
prevalence of antisocial personality disorder, psychosis and attention deficit and 
hyperactivity disorder (ADHD) (e.g. for recent reviews see Torrens et al., 2015; 
Kingston et al., 2016).  Biological and psychosocial differences between men 
and women influence the “prevalence, presentation, comorbidity, and treatment 
of substance use disorders” (Back et al., 2006).  
People who use substances and have a co-occurring mental health 
disorder compared to those who do not, have poorer outcomes for both 
disorders (Boden and Moos, 2009; Flynn and Brown, 2008; Magura et al., 
2009). They also report sexual and drug use risk behaviours which could 
increase the risk of blood borne viruses in this population (Khalsa et al., 2008), 
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and increased unemployment, homelessness and criminal behaviour (Krausz et 
al., 2013; Greenberg and Rosenheck, 2014). This profile contributes to the high 
treatment, legal and societal costs for people with comorbid disorders 
(DeLorenze et al., 2014; Whiteford et al., 2013). 
  While strong evidence of gender differences in comorbidity exists, there 
is a gap in understanding of the relationships between specific mental disorders 
and specific substance use disorders (Torrens et al., 2015), by gender.  Sordo 
et al. (2012) argue that “few studies have evaluated whether there are different 
predictive factors for men and women” and that such information is required to 
inform prevention, diagnosis and treatment.  The majority of previous research 
has been undertaken among clinical or general population samples.  This study 
also provides the opportunity to consider out of treatment drug users.  
The current study aimed to explore 1) gender differences in lifetime substance 
use and psychiatric disorders among people using different substances 
recruited from treatment and non-treatment settings; 2) risk factors for 
psychiatric disorders among substance users, independently by gender; and 3) 
associations between psychiatric disorders and substance use disorders, 
independently by gender. 
 
Methods 
Design, participants and settings 
Secondary analysis was conducted using data from 629 (201 females, 32.0%) 
users of illicit substances from five cross-sectional studies conducted in 
Barcelona, Spain during 2000-2006 (Torrens et al., 2011).  In total, 304 (82 
females, 27.0%) were recruited from treatment settings and 325 (119 females, 
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36.6%) were recruited from out of treatment settings.  One hundred and fifteen 
(38 females, 33.0%) consecutive admissions to an inpatient detoxification unit 
of a teaching hospital (Nocon et al., 2007) and 189 (44 females, 23.3%) 
consecutive admissions to three municipal outpatient low-threshold methadone-
maintenance programs (Astals et al., 2008) constituted the treatment sites.  A 
random sample of 139 (52 females, 37.4%) cocaine (Herrero et al., 2008) and 
149 (49 females, 32.9%) heroin users (Rodriguez-Llera et al., 2006) aged 18-30 
years were recruited from street sites using targeted sampling and nomination 
techniques as part of a larger cohort study (de la Fuente et al., 2005; Pulido et 
al., 2009).   Thirty seven (18 females, 48.6%) Ecstasy users aged 18-35 years 
were recruited via word of mouth in a pharmacological research unit to the 
study on the Neurotoxic Effects of Ecstasy (Martín-Santos et al., 2010). 
 
Instruments 
DSM-IV substance use (abuse or dependence) disorders (SUD) and Axis I 
(mood, anxiety, eating, psychotic and attention deficit and hyperactivity 
disorders) and Axis II (antisocial and borderline personality disorders) non-
substance use psychiatric disorders (non-SUD) were diagnosed using the 
Spanish Psychiatric Research Interview for Substance and Mental Disorders 
(PRISM) (Torrens et al., 2004). The PRISM differentiates between the expected 
effects of intoxication and withdrawal, and between primary (independent) and 
substance-induced disorders (Hasin et al., 1998). The PRISM was administered 
by trained psychologists or psychiatrists in all studies to assess patient 
demographics, and “current” (previous 12 months) and “past” (criteria were met 
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before the previous 12 months). Lifetime disorder categories were created for 
the purpose of this paper. 
Test-retest reliability (Hasin et al., 2006), inter-rater reliability (Morgello et 
al., 2006) and validity (Torrens et al., 2004) to diagnose psychiatric disorders 
among substance users, have been demonstrated using the PRISM.   
In addition to SUD and Non-SUD diagnoses, the following variables were 
included from each study: participants’ sex, age, civil status, highest level of 
education attained, employment status, living arrangements, drug use history, 
HIV and hepatitis C virus (HCV) status. 
 
Statistical Analysis  
Procedure 
Data were analysed using SPSS version 22. Descriptive statistics were 
calculated using frequencies and percentages for categorical data and means 
and standard deviations (SD) for continuous data. Odds ratios (OR) and 95% 
confidence intervals (CI) were calculated using binary logistic regression. 
Differences by gender of participant in demographics, lifetime substance use 
and non-SUD psychiatric disorders are presented in Table 1, with and without 
adjusting for study setting and age. Tables 2 and 3 describe the associations 
between lifetime non-SUD psychiatric disorders and substance use disorders, 
independently for females and males. Tables 4 and 5 describe the factors 
associated with lifetime non-SUD for females and males, respectively.  
 
Results  
Demographics  
Page 6 of 30Advances in Dual Diagnosis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Advances in Dual Diagnosis
 
7 
 
7
The majority of the sample was male (68%). The mean age of participants was 
28.6 years (SD 7.1).  After adjusting for age and study, females were 
significantly more likely to be married or cohabiting than males; were less likely 
to be employed or studying; or to have ever been imprisoned than males (Table 
1). Women were over twice as likely to be squatting or homeless as men 
(compared to living alone).  However, once the data were adjusted for age and 
study, the gender difference was no longer significant. 
 
Substance Use 
There were no differences by gender in the age of first use of cocaine, heroin or 
alcohol; or in the onset of habitual substance use.  After adjusting for age and 
study, females were significantly older than males when they first used 
cannabis (Table 1).  Almost 60% of males and 53% of females had ever 
injected drugs.  Approximately 20% of males and females were HIV 
seropositive.  There was no difference in the prevalence of HCV status between 
males and females (39% vs 48%). Females were less likely than males to meet 
criteria for any (abuse or dependence) substance use disorder, for poly 
substance use disorder and for heroin, cannabis and alcohol abuse or 
dependence disorders.  Males met criteria for a significantly greater number of 
lifetime substance use disorders than females (3.6 vs. 3.1) (Table 1). 
  
Axis I psychiatric disorders (non-SUD) 
The incidence of any Axis 1 psychiatric (non-SUD) disorder was 41.8%, with 
major depressive disorder (17%) being the most common.   The odds of having 
any non-SUD were over two times greater for females than males even after 
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adjusting for age and study (Table 1). After adjusting for age and study, females 
were over twice as likely as males to meet criteria for any mood disorder 
(including over two times as likely to meet criteria for major depressive 
disorder); almost two times as likely to meet criteria for any anxiety disorder 
(including over four times as likely to meet criteria for specific phobia, and over 
three times as likely to meet criteria for panic disorder with agoraphobia and 
PTSD);  and over three times as likely to meet criteria for an eating disorder. 
Females were less likely to meet criteria for attention deficit disorder than males 
after adjusting for age and study. There were no differences by sex for the 
proportion of participants meeting criteria for any substance induced disorders 
(Table 1). 
After adjusting for age and study, women who met criteria for a lifetime 
Axis I non-SUD psychiatric disorder were more likely than those who did not to 
have ever been in prison or to be HCV seropostitive (Table 2); and for men 
lower educational attainment or ever been in prison (marginally significant) were 
associated with a lifetime Axis I non-SUD psychiatric disorder (Table 3). 
 
Axis II personality disorders 
Over a fifth of the sample met criteria for antisocial or borderline personality 
disorders.  After adjusting for age and study, women were more likely than men 
to meet criteria for borderline personality disorder, and less likely than men to 
meet criteria for antisocial personality disorder (Table 1).   
 
Associations between specific lifetime SUD and psychiatric disorders 
(non-SUD) by sex 
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Tables 4 and 5 describe the associations between specific SUD and psychiatric 
disorders (non-SUD) for women and men respectively.  For women, alcohol or 
hallucinogen disorders increased the odds of having a mood disorder; cocaine 
and hallucinogen disorders increased the odds of having an anxiety disorder; a 
hallucinogen disorder increased the odds of having an eating disorder; sedative 
and stimulant disorders increased the odds of having a psychotic disorder; 
opiates, cocaine, cannabis and poly substance disorders increased the odds of 
having an antisocial or borderline personality disorder; and alcohol, cocaine, 
stimulants, cannabis, hallucinogens and poly substance disorders increased the 
odds of having a substance induced disorder. For men, cocaine and poly 
substance use disorders increased the odds of having a mood disorder; a 
stimulant disorder increased the odds of having an anxiety disorder; stimulant 
and hallucinogen disorders increased the odds of having an eating disorder; an 
alcohol disorder increased the odds of having a psychotic disorder; all 
substance use disorders (including poly substance use disorder) increased the 
odds of having an antisocial or borderline personality disorder; and cocaine and 
hallucinogen disorders increased the odds of having a substance induced 
disorder. 
 
Discussion 
Men were more likely than women to meet criteria for any substance use 
disorder, for poly substance use disorder and for heroin, cannabis and alcohol 
abuse or dependence disorders.  They were also more likely to report a greater 
number of lifetime substance use disorders than females.  
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Co-occurring disorders among people who use substances recruited 
from in and out of treatment settings is common. Over 4 in 10 participants 
(almost 4 in 10 men and over 5 in 10 women) included in the studies met 
criteria for any lifetime axis 1 psychiatric (non-SUD) disorder, and over 2 in 10 
men and women met criteria for any lifetime antisocial or borderline personality 
disorder.  The prevalence of any lifetime (non-SUD) axis I substance-induced 
disorders was substantially lower (15%) than primary or independent psychiatric 
disorders (64%). While lifetime mood and anxiety disorders were more likely to 
be independent disorders, psychotic disorders although less prevalent, were 
more likely to be substance induced disorders.  Contrary to other studies (Niciu 
et al., 2009; Schuckit et al., 2007), the current did not report significantly higher 
rates of substance-induced disorders among men. It is important for clinicians to 
distinguish between psychiatric disorders that are independent and those that 
are substance-induced have different risk factors, prognosis and treatment 
outcomes, with recent research highlighting an increased risk for relapse 
following treatment for those with  substance induced versus independent major 
depressive disorder (Connor et al., 2014; Foulds et al., 2015; Langas et al., 
2012; Samet et al., 2013; Torrens et al., 2011).  As a result, substance induced 
and independent psychiatric disorders may require different interventions and 
treatment approaches.  
   
Women were more likely than men to have ever had any mood disorder; 
any anxiety disorder; any eating disorder or borderline personality disorder; and 
men were more likely than females to have ever had antisocial personality 
disorder or attention deficit disorder.   Potential explanations for these gender 
differences have include that women who use substances have often 
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experienced greater adverse events in childhood and adulthood (including 
abuse, intimate partner violence, sex trading) than men who use substances 
(Afifi et al., 2012; Choo et al., 2014; Verona et al., 2015; Gilchrist et al., 2015) 
which may contribute to the higher prevalence of mood and anxiety disorders.  
In addition, a greater proportion of women report higher depression and anxiety 
disorders in childhood and adolescence than men, which is a risk factor for a 
recurrent episode (Gilchrist and Gunn, 2007).  Perhaps as a result of these 
issues, several studies have reported that for women, psychiatric disorders are 
more likely to predate the substance use disorder (Kessler, 2004).  
The odds of having a personality disorder in the current study were 
higher for both men and women with polysubstance use disorders.  For men 
personality disorders were associated with alcohol and drug use disorders, 
whereas for women they were associated with opiate, cocaine and cannabis 
use disorders. We found that borderline personality was more prevalent among 
females than males, and antisocial personality disorder was more prevalent 
among males than females. Lewis and Grenyer (2009) stress the role of trauma 
in the “etiology and phenomenology” of borderline personality disorder. Zanarini 
et al. (2005) found a higher prevalence of adulthood physical and sexual abuse 
among people with borderline personality disorder compared to patients with 
another personality disorders.  It has been suggested that the lower prevalence 
of antisocial personality disorder among women may be underestimated “due to 
the requirement of childhood conduct disorder symptoms” (Dolan and Völlm, 
2009, pp. 2) for a diagnosis. This includes physical aggression in adolescence 
that may result in more males than females being diagnosed.    
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Women who met criteria for a lifetime Axis I non-SUD psychiatric 
disorder were more likely to have ever been imprisoned or to be HCV 
seropostitive.  The increased prevalence of psychiatric disorders among men 
and women who use substances in the criminal justice service have been 
reported (eg. Prins, 2014; Torrens et al., 2015). While data were not collected 
on whether participants had received treatment for HCV, Martin-Santos et al. 
(2015) suggest that “both the hepatitis C infection and antiviral treatment 
(especially when using the pro-inflammatory cytokine interferon α), are 
highly associated with depression, where female gender constitutes a risk 
factor”. Also women who have experienced trauma report higher rates of 
depression (eg. Trevillion et al., 2012) and injecting risk behaviours (eg. 
Khalsa et al., 2008) attributed to hepatitis C acquisition, which may contribute 
to this finding.   
Similar to other studies, we found that men who met criteria for a lifetime 
Axis I non-SUD psychiatric disorder were more likely to only have a primary 
education, to have ever been in prison (marginally significant) or to be 
unemployed or receiving benefits (Krausz et al., 2013; Greenberg and 
Rosenheck, 2014). 
 
Strengths and limitations 
This secondary analysis is limited as it includes five cross-sectional studies, 
therefore it was not possible to determine causality only associations. Despite 
these limitations, the study included a large sample size allowing sufficient 
power to examine differences between men and women. Finally, an additional 
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strength of the methodology is the use of the gold standard PRISM which was 
used to assess disorders. 
 
Implications for practice 
Being female does not predict the outcome of substance use treatment 
(Greenfield et al., 2007). However, comorbid psychiatric disorders and sexual 
and physical abuse, both of which are higher among female than male 
substance users, are associated with poorer treatment outcomes (Greenfield et 
al., 2002; Flynn and Brown, 2008; Boden and Moos, 2009; Magura et al., 2009). 
Treatment systems are often separated for mental health and substance abuse 
(Saitz et al., 2008).  Evidence supports the integration of treatment for people 
who use substances with co-existing psychiatric disorders (Kelly and Daley, 
2013).  While women-only treatment is not necessarily more effective than 
mixed-gender treatment, some greater effectiveness has been demonstrated by 
treatments that address problems more common to women or that are designed 
for specific subgroups of this population (Greenfield et al., 2009). 
 
Conclusions 
Our results show that psychiatric disorders are common among people who use 
substances. Gender differences were reported for various disorders. Around 5 
in 10 men and 6 in 10 women recruited from out of treatment had an Axis I non-
SUD psychiatric disorder, highlighting the need to increase access to both 
substance use and mental health treatment for people who use substances, 
especially those not in treatment.   Integrated treatment should be provided to 
address psychiatric comorbidity among people who use substances, and 
Page 13 of 30 Advances in Dual Diagnosis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Advances in Dual Diagnosis
 
14 
 
14
gender specific approaches considered to improve outcomes for this population. 
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Table 1.  Demographics, lifetime substance use and other non-substance use psychiatric disorders by gender of participant 
 
 Total 
n=629
a
 
Male 
n=428
a
 
Female 
n=201
a
 
Unadjusted  
OR 
95% CI Adjusted 
OR for 
study
(1-5)
 & 
age 
 
95% CI 
 n % n % n %     
Recruited out of 
treatment 
325 51.7 206 48.1 119 59.2 1.56 (1.11, 2.20) 1.24 (0.81, 1.90) 
           
Age [mean (SD)]   
 
Civil status 
28.6 (7.1) 29.2 (7.0) 27.4 (7.0) 0.96 (0.94, 0.99) 0.98 (0.95, 1.01) 
Single/Never married/ 
Divorced/ separated/ 
widowed 
Married/ cohabiting                                  
411 
 
  
146
65.3 
 
  
23.2 
345 
 
  
83 
80.6 
 
  
19.4 
138 
 
  
63 
68.7 
 
  
31.3 
1.00 
 
  
1.90 
- 
 
  
(1.30, 2.78) 
 
1.00 
 
  
2.31 
- 
 
  
(1.55, 3.45) 
Living arrangements           
Lives Alone 
Lives with partner/ 
family/ friends/ 
flatmate 
Squatting/ homeless 
  
70 
449 
 
 
108 
11.2 
71.6 
 
 
17.2 
52 
311 
 
 
63 
12.2 
73.0 
 
 
14.8 
18 
138 
 
 
45 
9.0 
68.7 
 
 
22.4 
1.00 
1.28 
 
 
2.06 
- 
(0.72, 2.27) 
 
 
(1.07, 3.99) 
 
1.00 
1.09 
 
 
1.56 
 
- 
(0.60, 1.95) 
 
 
(0.79, 3.10) 
Education           
No schooling/ no 
school certificate/ 
primary studies 
Secondary or 
University studies 
 
 
334 
 
 
295 
 
53.1 
 
 
46.9 
 
 
228 
 
 
200 
 
53.3 
 
 
46.7 
 
106 
 
 
95 
 
52.7 
 
 
47.3 
 
1.00 
 
 
1.02 
 
- 
 
 
(0.73, 1.43) 
 
    1.00 
 
 
0.95 
 
 
- 
 
 
(0.65, 1.35) 
Employment            
Not working or 
Studying 
335 
 
53.5 
 
216 
 
50.7 
 
119 
 
59.5 
 
1.00 
 
- 
 
1.00 
 
- 
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 Total 
n=629
a
 
Male 
n=428
a
 
Female 
n=201
a
 
Unadjusted  
OR 
95% CI Adjusted 
OR for 
study
(1-5)
 & 
age 
 
95% CI 
 n % n % n %     
Working or studying                   291 46.5 210 49.3 81 
 
40.5 
 
0.70 (0.50, 0.98) 0.69 (0.49, 0.98) 
Ever imprisoned 417 70.4 268 62.8 87 43.5 0.46 (0.33,  0.64) 0.47 (0.32, 0.69) 
           
Age first used 
[mean (SD)]
b-d
   
          
Cannabis  
Heroin                                                      
Alcohol  
Cocaine 
Hallucinogen 
15.6 
19.8
15.0 
18.7 
18.1 
(3.1) 
(5.2) 
(3.1) 
(4.9) 
(3.6) 
15.4 
19.8 
14.9 
18.9 
18.1 
(3.1) 
(5.0) 
(3.2) 
(5.1) 
(3.4) 
15.9 
19.9 
15.4 
18.2 
18.3 
(2.9) 
(5.6) 
(2.9) 
(4.4) 
(4.3) 
1.05 
1.00 
1.00 
0.97 
1.01 
(0.97, 1.11) 
(0.97, 1.04) 
(0.95, 1.07) 
(0.93, 1.00) 
(0.92, 1.12) 
1.09 
1.04 
1.00 
1.01 
1.04 
(1.03, 1.16) 
(0.99, 1.08) 
(0.93, 1.06) 
(0.96, 1.05) 
(0.93, 1.15) 
           
Injected in 
lifetime 
627 99.7 255 59.9 106 52.7 0.75 (0.53, 1.05) 0.97 
 
(0.66, 1.43) 
HIV 588 93.5 79 19.5 36 19.8 1.02 (0.66, 1.58) 1.23 (0.78, 1.95) 
Hepatitis C 264 45.3 193 48.0 71 39.2 0.70 (0.49, 0.999) 0.85 (0.58, 1.25) 
           
Lifetime 
substance abuse 
or dependence 
disorders (SUD)
g 
          
Any SUD 589 93.6 409 95.6 180 89.6 0.40 (0.21, 0.76) 0.54 (0.27, 1.10) 
Poly SUD
e 
528 83.9 373 87.1 155 77.1 0.50 (0.32, 0.77) 0.55 (0.34, 0.88) 
Opiates
f
  450 71.5 317 74.1 133 66.2 0.69 (0.48, 0.99) 1.57 (0.71, 3.48) 
Cocaine   476 75.7 330 77.1 146 72.6 0.79 (0.54, 1.16) 0.82 (0.55, 1.24) 
Stimulant   209 33.2 145 33.9 64 31.8 0.91 (0.64, 1.30) 0.84 (0.58, 1.23) 
Hallucinogen   143 22.7 103 24.1 40 19.9 0.65 (0.42, 1.00) 0.78 (0.52, 1.18) 
Cannabis   331 52.6 252 58.9 79 39.3 0.45 (0.32, 0.64) 0.46 (0.32, 0.65) 
Sedatives    201 32.2 132 30.8 69 34.3 1.17 (0.82, 1.67) 1.41 (0.93, 2.12) 
Alcohol   305 48.5 223 52.1 82 40.8 0.63 (0.45, 0.89) 0.61 (0.42, 0.86) 
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 Total 
n=629
a
 
Male 
n=428
a
 
Female 
n=201
a
 
Unadjusted  
OR 
95% CI Adjusted 
OR for 
study
(1-5)
 & 
age 
 
95% CI 
 n % n % n %     
           
Number SUD
g
 
[mean (SD)]   
 
Psychiatric non-
SUD disorders
g
  
 
3.4 (1.9) 3.6 (1.8) 3.1 (1.9) 0.87 (0.79, 0.95) 0.86 (0.78, 0.96) 
Any Axis 1 
psychiatric 
(Non-SUD) 
disorder  
263 41.8 154 36.0 109 54.2 2.11 (1.50, 2.96) 2.09 (1.48, 2.96) 
 
Any substance 
induced 
disorder 
 
 
95 
 
 
15.1 
 
 
58 
 
 
13.6 
 
 
37 
 
 
18.4 
 
 
1.44 
 
 
(0.92, 2.26) 
 
 
1.34 
 
 
(0.85, 2.12) 
           
Any mood 
disorder 
170 27.0 94 22.0 76 37.8 2.16 (1.50, 3.11) 2.13 (1.46, 3.11)  
Dysthymia 11 1.7 8 1.9 3 1.5 0.79 (0.21, 3.03) 1.12 (0.20, 6.24) 
Major 
depressive 
disorder  
107 17.0 55 12.9 52 25.9 2.37 (1.55, 3.62) 2.42 (1.57, 3.72) 
Hipomania  1 0.2 1 0.2 0 0 - - - - 
Substance 
induced 
affective 
disorder  
 
63 10.0 39 9.1 24 11.9 1.35 (0.79, 2.32) 1.27 (0.73, 2.21) 
Any anxiety 
disorder 
97 15.4 55 12.9 42 20.9 1.79 (1.15, 2.79) 1.86 (1.19, 2.92) 
General anxiety 3 0.5 1 0.2 2 1.0 4.29 (0.39, 47.61) 3.80 (0.34, 42.19) 
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 Total 
n=629
a
 
Male 
n=428
a
 
Female 
n=201
a
 
Unadjusted  
OR 
95% CI Adjusted 
OR for 
study
(1-5)
 & 
age 
 
95% CI 
 n % n % n %     
disorder 
Specific phobia  25 4.0 9 2.1 16 8.5 4.30 (1.88, 9.83) 4.73 (2.05, 10.96) 
Social phobia  
Panic disorder 
21 
32 
3.3 
5.1 
19 
19 
4.4 
4.4 
5 
13 
2.5 
6.5 
0.55 
1.49 
(0.20, 1.49) 
(0.72, 3.08) 
0.61 
1.58 
(0.22, 1.67) 
(0.76, 3.31) 
Obsessive 
compulsive  
7 1.1 7 1.6 0 0 - - - - 
PTSD  19 3.0 7 1.6 12 6.0 3.82 (1.48, 9.85) 4.31 (1.65, 11.28) 
Substance 
induced anxiety 
disorder    
 
7 1.1 5 1.2 2 1.0 -     
Any psychotic 
disorder 
44 7.0 30 7.0 14 7.0 0.99 (0.52, 1.92) 1.05 (0.54, 2.06) 
Schizophrenia  11 1.7 10 2.3 1 0.5 0.21 (0.03, 1.64) 0.23 (0.03, 1.85) 
Schizoaffective  1 0.2 1 0.2 0 0 - - - - 
Lifetime 
Psychotic 
disorder  
13 2.1 12 2.8 1 0.5 - - - - 
Substanced 
induced 
psychotic 
disorder  
31 4.9 18 4.2 13 6.5 1.57 (0.76, 3.28) 1.53 (0.73, 3.21) 
           
Attention 
deficit disorder 
50 7.9 41 9.6 9 4.5 0.44 (0.21, 0.93) 0.37 (0.17, 0.78) 
           
Any eating 
disorder 
33 5.2 13 3.0 20 10.0 3.53 (1.72, 7.25) 3.01 (1.45, 6.25) 
Anorexia   10 1.6 2 0.5 8 4 8.83 (1.86, 41.97) 8.58 (1.77, 41.54) 
Bulimia         13 2.1 2 0.5 11 5.5 12.33 (2.71, 56.17) 10.35 (2.25, 47.58) 
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 Total 
n=629
a
 
Male 
n=428
a
 
Female 
n=201
a
 
Unadjusted  
OR 
95% CI Adjusted 
OR for 
study
(1-5)
 & 
age 
 
95% CI 
 n % n % n %     
Eating disorder 
NOS
h 
14 2.2 10 2.3 4 2.0 0.85 (0.26, 2.74) 0.66 (0.20, 2.20) 
           
Antisocial or 
borderline 
personality 
disorder 
144 22.9 101 23.6 43 21.4 0.88 (0.59, 1.32) 0.84 (0.55, 1.29) 
Antisocial  104 16.5 79 18.5 25 12.4 0.63 (0.39, 1.02) 0.59 (0.36, 0.96) 
Borderline  67 10.7 34 7.9 33 16.4 2.28 (1.36, 3.80) 2.29 (1.37, 3.84) 
 
 
Footnotes 
Extremely low cell count for some variables precluded statistical analysis. 
1 
Nocon A, Berge D, Astals M, Martín-Santosa R, Torrens M. Dual diagnosis in an inpatient drug-abuse detoxification unit. Eur Addict Res. 2007,13(4):192-200.   
2 
Astals M, Domingo-Salvany A, Castillo C, Tato J, Vázquez JM, Martín-Santos R, Torrens M. Impact of substance dependence and dual diagnosis on the quality of life of 
heroin users seeking treatment. Subst Use Misuse. 2008,43(5):612-632. 
3
 Rodriguez-Llera MC, Domingo-Salvany A, Brugal MT, Silva TC, Sánchez-Niubó A, Torrens M,  ITINERE Investigators.  Psychiatric comorbidity in young heroin users Drug 
Alcohol Depend. 2006,84(1):48-55   
4
 Herrero MJ, Domingo-Salvany A, Torrens M, Brugal MT. the ITINERE Investigators. Psychiatric comorbidity in young cocaine users: induced versus independent disorders. 
Addiction. 2008,103(2):284-293. 
5 
Martín-Santos R, Torrens M, Poudevida S, Langhor K, Cuyas E, Pacific R, Farré M, Pichini S, de la Torre Fornell R. 5-HTTLPR polymorphism, mood disorders and MDMA use 
in a 3-year follow-up study. Addict Biol. 2010,15:15-22. 
a
 Discrepancies in totals due to missing responses 
b
 For young heroin and young cocaine users, the age of first alcohol and cannabis use was calculated from the youngest age of the following two variables: age began 
chronic use (i.e. ≥ 4 days a week during a month for cannabis, and ≥ 5 drinks per day for ≥ 4 days a week during a month for alcohol) and age began using most of the day 
for 3 consecutive days for cannabis, and using ≥ 5 drinks for 3 consecutive days for alcohol
 
c 
With the exception of Ecstasy users and inpatient detoxification patients where age of first use of any substance was calculated, age of habitual use refers to the youngest 
age of the following two variables: age began chronic use (i.e. ≥ 4 days a week during a month for drugs, and ≥ 5 drinks per day for ≥ 4 days a week during a month for 
alcohol) and age began using most of the day for 3 consecutive days for drugs, and using ≥ 5 drinks for 3 consecutive days for alcohol 
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d 
Any substance abuse or dependence includes heroin, methadone and other opiates (analgesics), cocaine, stimulants, hallucinogens, cannabis, sedatives, alcohol and other 
drugs 
e
 Poly substance abuse/dependence is abuse/dependence of more than one substance 
f
 Any opiate abuse or ependence includes heroin, methadone and other opiates (analgesics) 
g 
SUD: Substance use (abuse or dependence) disorder/s  
h 
NOS: Not otherwise specified 
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Table 2. Factors associated with Lifetime Axis I Non Substance Use Disorder (non-SUD) among females who use 
substances 
  
 No lifetime 
Axis 1 non 
SUD 
Lifetime Axis 1 
non SUD 
 
Unadjusted OR and 
95% CI 
OR and 95% CI Adjusted 
for age and study 
Demographics 
Marital status 
    
Single/Never married/ 
Divorced/Separated/Widowed 
72.8% 65.1% 1.00 1.00 
Married/Cohabiting 27.2% 24.9% 0.70 (0.28, 1.28) 0.71 (0.38, 1.31) 
     
Highest level of education 
attained 
    
Secondary school or university 
studies (versus no or primary 
schooling) 
46.7% 47.7% 1.04 (0.60, 1.81) 1.06 (0.59, 1.88) 
Employment     
Working or studying 42.4% 38.9% 0.86 (0.49, 1.52) 0.86 (0.48, 1.55) 
Criminal history     
Ever in prison 33.0% 52.3% 2.23 (1.25, 3.97) 2.57 (1.35, 4. 86) 
Living arrangements     
Lives alone 5.4% 11.9% 1.00 1.00 
Flatmate/family 72.8% 65.1% 0.41 (0.14, 1.21) 0.41 (0.14, 1.21) 
Squatting/homeless 21.8% 22.9% 0.48 (0.15, 1.58) 0.50 (0.15, 1.68) 
Blood borne virus status     
HIV  
Hepatitis C 
17.3%                 
28.4% 
21.8% 
48.0% 
1.33 (0.63, 2.81) 
2.33 (1.24, 4.34) 
1.36 (0.62, 2.96) 
3.05 (1.48, 6.29) 
Recruited from out 
of treatment settings 
58.7% 59.6% 1.04 (0.59, 1.83)  1.99 (0.58, 6.80)  
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Table 3. Factors associated with Lifetime Axis I Non Substance Use Disorder (non-SUD) among males who use 
substances   
 No lifetime 
Axis 1 non SUD 
Lifetime Axis 1 
non SUD 
 
Unadjusted OR 
and 95% CI 
OR and 95% CI 
Adjusted for age 
and study 
Marital status     
Single/Never married/ 
Divorced/Separated/Widowed 
78.1% 85.1% 1.00 1.00 
Married/Cohabiting 21.9% 14.9% 1.60 (0.94, 2.71) 1.56 (0.90, 2.57) 
Highest level of education 
attained 
    
Secondary school or university 
studies (versus no or primary 
schooling) 
50.0% 40.9% 0.69 (0.46, 1.03) 0.63 (0.42, 0.95) 
Employment     
Working or studying 52.9% 42.8% 0.66 (0.45, 0.99) 0.67 (0.45, 1.01) 
Criminal history     
Ever in prison 60.4% 66.9% 1.32 (0.87, 2.00) 1.51 (0.98, 2.34) 
Living arrangements     
Lives alone 12.4% 11.8% 1.00 1.00 
Flatmate/family 74.5% 70.4% 0.99 (0.53, 1.84) 0.85 (0.50, 1.80) 
Squatting/ homeless 13.1% 17.7% 1.42 (0.66, 3.03) 1.32 (0.59, 2.92) 
Blood borne virus status     
HIV 
Hepatitis C 
21.2% 
46.1% 
16.3% 
51.4% 
0.72 (0.43, 1.23) 
1.23 (0.82, 1.86) 
0.75 (0.44, 1.29) 
1.40 (0.91, 2.17) 
Recruited from out 
of treatment settings 
    46.4% 51.3% 1.22 (0.82, 1.81)    0.79 (0.32, 1.94)  
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Table 4.  Associations between specific Lifetime Substance Use Disorders and Non Substance Use Disorder among females who use substances   
 
Lifetime 
substance use 
disorders  
OR (95%CI) 
Lifetime (non-substance use) psychiatric disorders OR (95%CI) 
 Mood  Anxiety  Eating  Psychotic  Antisocial and/or borderline 
personality  
Any substance induced  
Alcohol 1.84 (1.03, 3.29) 1.82 (0.92, 3.60) 1.21 (0.48, 3.07) 1.10 (0.37, 3.28) 1.71 (0.87, 3.37) 2.92 (1.40, 6.11) 
Opiates 1.58 (0.85, 2.93) 1.58 (0.74, 3.37)   0.59 (0.23, 1.50) 7.26 (0.93, 56.71) 2.68 (1.17, 6.16) 1.75 (0.77, 3.95) 
Cocaine 1.36 (0.71, 2.60) 2.67 (1.06, 6.76) 2.28 (0.64, 8.13) 5.28 (0.67, 41.35) 10.34 (2.41, 44.43) 2.81 (1.03, 7.63) 
Sedatives 1.44 (0.79, 2.61) 1.40 (0.70, 2.82) 0.45 (0.14, 1.39) 3.81 (1.22, 11.86) 1.93 (0.97, 3.85) 1.93 (0.89, 3.78) 
Stimulants  1.31 (0.71, 2.40) 1.62 (0.80, 3.28) 2.35 (0.93, 5.98) 3.12 (1.03, 9.41) 1.54 (0.77, 3.11) 2.12 (1.02, 4.39) 
Cannabis  1.32 (0.74, 2.36) 1.06 (0.53, 2.13) 1.62 (0.64, 4.10) 3.01 (0.97, 9.34) 4.47 (2.18, 9.20) 3.66 (1.73, 7.74) 
Hallucinogens 2.13 (1.06, 4.29)  2.19 (1.01, 4,75) 3.10 (1.17, 8.21) 0.65 (0.14, 3.05) 1.80 (0.82, 3.93) 2.75 (1.25, 6.06) 
Poly substance 1.52 (0.75, 3.09) 2.57 (0.95, 6.98) 0.88 (0.30, 2.56) - 7.91 (1.83, 34.11) 6.42 (1.48, 7.80) 
Footnote: Extremely low cell count for some variables precluded statistical analysis. 
 
Table 5.  Associations between specific Lifetime Substance Use Disorders and Non Substance Use Disorder among males who use substances   
 
Lifetime 
substance use 
disorders  
OR (95%CI) 
Lifetime (non-substance use) psychiatric disorders OR (95%CI) 
 Mood  Anxiety  Eating  Psychotic  Antisocial and/or 
borderline personality  
Any substance induced  
Alcohol 1.32 (0.83, 2.10) 1.22 (0.69, 2.15) 2.11 (0.64, 6.97) 2.70 (1.17, 6.20) 2.89 (1.77, 4.69) 1.60 (0.91, 2.83) 
Opiates 0.73 (0.44, 1.21) 1.03 (0.54, 1.97) 0.78 (0.24, 2.59)  1.82 (0.68, 4.86) 2.18(1.21, 3.91) 0.82 (0.45, 1.51) 
Cocaine 2.13 (1.13, 4.02) 0.95 (0.49, 1.86) 0.99 (0.27, 3.67) 1.53 (0.57, 4.09) 3.35 (1.67, 6.73) 4.60 (1.62, 13.04) 
Sedatives 1.07 (0.65, 1.74) 1.74 (0.97, 3.11) 1.00 (0.30, 3.30) 0.96 (0.43, 2.15) 3.88 (2.43, 6.20) 1.57 (0.89, 2.79) 
Stimulants 1.21 (0.75, 1.95) 1.91 (1.08, 3.39) 3.25 (1.04, 10.11) 0.83 (0.37, 1.85) 3.33 (2.10, 5.28) 1.71 (0.98, 3.01) 
Cannabis  1.38 (0.86, 2.23) 1.83 (0.99, 3.39)  0.81 (0.27, 2.45) 0.59 (0.28, 1.24) 1.91 (1.18, 3.08) 1.39 (0.78, 2.47) 
Hallucinogens 1.57 (0.94, 2.61) 1.49 (0.80, 2.78) 3.88 (1.27, 11.81) 0.78 (0.31, 1.95) 2.58 (1.59, 4.20) 2.38 (1.33, 4.26) 
Poly substance 4.06 (1.43, 11.53) 2.02 (0.70, 5.83) 1.80 (0.23, 14.08) 4.55 (0.61, 34.11) 19.78 (2.70, 144.88) - 
Footnote: Extremely low cell count for some variables precluded statistical analysis. 
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